Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

Core Insights - Evofem Biosciences, Inc. is focused on addressing unmet needs in women's sexual and reproductive health through innovative products [3] Group 1: Recent Developments - Evofem has acquired global rights to SOLOSEC® (secnidazole) 2 g oral granules, an antibiotic for treating bacterial vaginosis and trichomoniasis [2] - The company has licensed commercial rights to Phexxi® (lactic acid, citric acid, and potassium bitartrate) contraceptive gel in the Middle East to Pharma 1 Drug Store [2] - A partnership with Hello Alpha has been established to offer Phexxi as a hormone-free contraception solution, targeting women on GLP-1s and those seeking hormone-free birth control [2] Group 2: Upcoming Events - Evofem's CEO Saundra Pelletier and Chief Business Development Officer Amy Raskopf will present at the OTCQB Venture Virtual Investor Conference on August 1, 2024, at 10:30 am ET [1] Group 3: Product Offerings - Phexxi® is an FDA-approved, hormone-free, on-demand contraceptive vaginal gel, applied 0-60 minutes before sexual intercourse [3] - SOLOSEC® provides a complete course of therapy for bacterial vaginosis and trichomoniasis in a single dose, approved for individuals aged 12 and older [3] Group 4: Merger Agreement - In December 2023, Evofem entered into a Merger Agreement with Aditxt, Inc., with plans to close the transaction in the second half of 2024 [4]